No Overall Survival Benefit Observed with Second-Line Vandetanib in Advanced NSCLC

Share this content:

(ChemotherapyAdvisor) – In patients with advanced non–small-cell lung cancer (NSCLC) previously treated with an EGFR tyrosine kinase inhibitor and one or two chemotherapy regimens, vandetanib did not demonstrate an overall survival (OS) benefit vs. placebo, results of the multicenter, randomized, phase 3 ZEPHYR study reported in the Journal of Clinical Oncology online February 27.

The double-blind, placebo-controlled study randomly assigned patients 2:1 to receive vandetanib 300mg/day (n=617) or placebo (n=307); both groups also received best supportive care. Compared with placebo, no significant increase in OS, the primary end point, was detected in the vandetanib cohort (HR=0.95; P=0.527). Median OS was 8.5 months in the vandetanib group vs. 7.8 months for placebo.

For the secondary end points of progression-free survival and objective response rate, statistically significant advantages favored vandetanib, the investigators reported. Consistent with previous studies of the vandetanib 300mg dose in patients with NSCLC, some adverse events were higher with vandetanib than placebo; these included diarrhea (46% vs. 11%), rash (42% vs. 11%), and hypertension (26% vs. 3%).

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs